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940Objectives: Loss of epithelial cells is one of the key factors that lead to airway fibrosis. Loss of epithelial cells
may decrease the barrier to host cell infiltration into the lumen, allowing deposition of extracellular matrix, with
subsequent obliteration of the airway. The objective of this study was to determinewhether injection of epithelial
cells/progenitor cells from the recipient into the lumen of the donor trachea could prevent bronchiolitis obliter-
ans (BO) in a mouse heterotopic tracheal transplantation (HTT) model.
Methods: A major histocompatibility complex class I and class II mismatch of mouse HTT model of BO was
used. Epithelial cells from recipient mice were isolated and reinjected into the lumen of the allografts on day 3
after transplantation. Rag-1 knock-out and isografts were also performed as controls. The grafts were analyzed
by immunohistochemistry and densitometric analysis.
Results: The results demonstrated that tracheal epithelium was lost by day 3, regenerated between 3 to 7 days,
and was lost again in all allografts, but not in the isografts or in Rag-1 knock-out groups by day 12. The recon-
stituted epitheliumwas donor originated on day 7 based on green fluorescent protein staining. Furthermore, with
the injection of recipient cells into the tracheal lumen, loss of the epithelium was not observed and the luminal
obliteration was significantly less in the allografts.
Conclusions: Injection of recipient epithelial cells prevents the second phase of epithelial loss and significantly
decreases BO development in an HTT model. Clinically, the use of injected recipient epithelial cells could be
a novel treatment for BO. (J Thorac Cardiovasc Surg 2013;145:940-7)Supplemental material is available online.
Lung transplantation is currently recognized as the preferred
treatment for selected patients with end-stage pulmonary
diseases. Despite notable advances since its inception,
long-term mortality of lung recipients is still highest among
all solid organs transplanted. The Achilles’ heel of lung
transplantation remains chronic allograft rejection.1,2
Chronic lung allograft rejection is also called bronchiolitis
obliterans (BO) and histologically is a temporal process
with loss of luminal epithelium, peribronchiolar leukocyte
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The Journal of Thoracic and Cardiovascular Surgairways.2,3 Once BO develops, progressive decline in
pulmonary function is typical. Unfortunately, BO responds
poorly to standard immunosuppression, and most patients
die of respiratory failure within 5 years of onset.
We4 and others6 have used a preclinical, widely described
mouse heterotopic tracheal transplant (HTT) model to
better understand the mechanisms involved in BO. It is
known from these studies that once the epithelial cells are
lost, the basement membrane is exposed and fibroblasts/
myofibroblasts infiltrate into lumen and secrete extracellu-
lar matrix, with the subsequent development of fibrosis.
Mukaida and associates7 reported that the regenerated epi-
thelial cells were of donor phenotype on day 10 but changed
to recipient phenotype after day 50 in a cryopreserved tra-
cheal allotransplantation dog model. Similarly, Ikonen,8
Adams,9 and their associates demonstrated that regenerated
epithelial cells were of donor phenotype on day 7 but
switched to recipient phenotype on days 30 and 60 in ortho-
topic tracheal allografts in a nonimmunosuppressed rat
model. The origin of regenerated epithelial cells has not
been reported in the mouse tracheal transplantation model.
Some have proposed that circulating recipient epithelial
cells may also contribute to repair.10,11 Published data
have shown that stem cells are involved in airway
epithelium repair.12-14 We hypothesized that a chimeric
epithelium (of donor and recipient origin) would be less
immunogenic and potentially be protective against theery c April 2013
Abbreviations and Acronyms
BO ¼ bronchiolitis obliterans
GFP ¼ green fluorescent protein
HTT ¼ heterotopic tracheal transplant
KO ¼ knock-out
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to test our hypothesis that the prevention of the secondary
loss of epithelial cells could prevent BO development. To
prevent this secondary loss, we injected recipient
epithelial cells into the donor tracheas after the initial loss
and during the regenerative phase with the goal of
creating a chimeric epithelium that would be more
tolerant. In this study, we tried to explore whether
injection of epithelial progenitor cells from recipients into
the donor trachea would prevent BO development by
preserving the second loss of epithelium cell.*HEPES¼ 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; DMEM¼Dulbecco’s
modified Eagle’s medium.MATERIALS AND METHODS
Animals
For tracheal transplant experiments, Balb/c male mice, C57BL6 male
mice were purchased from Jackson Laboratory, Bar Harbor, Maine. Green
fluorescent protein (GFP; C57BL6 background) male mice were from Lin-
den’s Laboratory (28-35 g). Rag-1 knock-out (KO, C57BL6 background)
male mice were kindly donated from the laboratory of Dr Victor Laubach.
According to the published results, Rag-1 KO mice have no functional
T and B cells.15 However, they have normal levels of functional natural
killer cells. All the experimental mice received humane care in accordance
with the ‘‘Principles of Laboratory Animal Care,’’ formulated by the
National Society for Medical Research, and ‘‘The Guide for the Care
and Use of Laboratory Animals,’’ prepared by the National Academy of
Science and published by the National Institutes of Health. The study pro-
tocol was approved by the Animal Care and Use Committee at the Univer-
sity of Virginia before experimentation.
Mouse Model of HTT
We used a heterotopic subcutaneous tracheal transplant model of BO as
described in our previous publications.4,5 In brief, a major
histocompatibility complex class I and class II mismatch was produced
by tracheal transplanting between Balb/c (H-2d) tracheas and C57BL/6
or the other way around.
Experimental Group Design
Experimental mice were divided into 4 groups: (1) Balb/c tracheas
transplanted to C57BL/6, GFP, and Rag-1 KO; (2) GFP tracheas trans-
planted to Balb/c mice; (3) Balb/c tracheas transplanted to GFP mice
treated with GFP-epithelial cells; (4) C57BL/6 tracheas transplanted to
C57BL/6 as isograft controls. In all groups, 4 donor tracheas were trans-
planted into 1 recipient; 3 recipients were used in each group and each
time point (days 3, 7, 12, 21, and 28). A total of 60 donors and 15 recipients
were used in each group. The mice were humanely killed and the isograft
and allografts were collected on days 3, 7, 12, 21, or 28 for histologic ex-
amination and immunhistochemical staining.
Isolation of Murine Tracheal Epithelial Cells
Mice (C57BL/6 or GFP, the same strain of mice as recipients) were hu-
manely killed and a total of 12 tracheas were isolated and washed withThe Journal of Thoracic and CaHEPES-DMEM* buffer supplemented with 1% penicillin–streptomycin
(Invitrogen, Grand Island, NY). The isolated trachea was placed into a 60-
mm cell culture dish. Next, 50 mL of digestion media, which contains
DMEM with 0.01% collagenase A (Roche Diagnostics, Mannheim, Ger-
many) and 1% penicillin–streptomycin, was injected into the lumen of the
isolated trachea and incubated for 1 hour in 5% carbon dioxide at 37C.
The tracheas were turned over every 15 minutes. Then the lumina were
flushed with 1XPBS containing 1% penicillin–streptomycin. The collected
epithelium-rich solutionwas centrifuged at 600 rpm for 5minutes. The cells
were confirmed by staining with keratins (K14 and K5) antibodies and cell
numbers were counted using a hemacytometer under microscopy. Then the
cells from each trachea were resuspended in phosphate-buffered saline
solution (30 mL), which is supplied with 1% penicillin–streptomycin. The
digested tracheas were immediately fixed in 4% zinc–formalin. After
24 hours, they were embedded in paraffin, sectioned, and stained for histo-
logic examination.
Injection of the Isolated Epithelial Cells into the
Lumen of the Allograft
On the third day after tracheal transplantation, the recipient mice were
anesthetized. An incision was made to expose the transplanted trachea
followed by the injection of the isolated epithelial cells directly into the
lumen of the allografts. The isolated epithelial cells (30 mL) from each tra-
chea were injected into 1 allograft only with a syringe. The same volume
(30 mL) of 1XPBS supplied with 1% penicillin–streptomycin was also in-
jected into each allograft in the control group.
Histology
Transplanted tracheal tissueswere collected and immediately fixed in 4%
zinc–formalin, After 24 hours they were embedded in paraffin, sectioned,
and stained with hematoxylin and eosin or with anti-mouse macrophage
(Mac-2; Accurate Chemical & Scientific Corporation, Westbury, NY),
anti-neutrophil, anti-CD3, and anti-GFP antibodies. Collagen deposition
was detected by direct red 80 collagen staining.
Immunohistochemical staining of macrophages and
neutrophils. Macrophages and neutrophils were detected by immuno-
histochemical analysis as described previously.4,5 In brief, rat anti-mouse
neutrophil (AbD Serotec, Raleigh, NC) or rat Mac-2 antibodies were
used as primary antibodies. Alkaline phosphatase–conjugated anti-rat im-
munoglobulin G (Sigma Chemical Company, St Louis, Mo) was used as
secondary antibody. Fast-Red (Sigma) was used as substrate. Purified
normal rat immunoglobulin G (eBioscience Inc, San Diego, Calif) was
used as a negative control. The sections were counterstained lightly with
hematoxylin for viewing negatively stained cells. Macrophage and neutro-
phil infiltration was semiquantified using Image-Pro Plus software (Media
Cybernetics, Rockville, Md). The densitometric value of positive staining
area of each section was blindly selected and measured.
Immunohistochemical staining of CD3þT cells. The stain-
ing was performed according to our previous publications.4,5,16 In brief, the
transplanted tracheal sections (5 mm) were dehydrated and incubated with
1% hydrogen peroxide. Sections were then boiled in Unmasking Solution
(Vector Laboratories, Burlingame, Calif) and blocked with 10% serum.
Goat anti-mouse CD3ε antibody (Santa Cruz Biotechnology, Santa Cruz,
Calif) is a primary antibody. After incubation with an avidin–biotin com-
plex, immunoreactivity was visualized by incubating the sections with 3,
3-diaminobenzidine tetrahydrochloride (Dako Corporation, Carpinteria,
Calif) to produce a brown precipitate and then counterstained with hema-
toxylin. The number of CD3þT cells per high-power field was assessed by
immunohistochemical staining of tracheal sections, and at least 5 fieldsrdiovascular Surgery c Volume 145, Number 4 941
FIGURE 1. Representative pictures of hematoxylin and eosin staining of the allograft from 3, 7, 12, and 21 days after transplantation. The magnification of
all the pictures was 403.Black arrows indicate epithelial cells. The gray arrows indicate basal cells. The donors are Balb/c mice and the recipients are Rag-1
KO and C57BL/6 wild-type mice. C57BL/6 to C57BL/6 isograft controls are also performed.
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was used for statistical analysis.
Measurement of the luminal obliteration. The luminal oblit-
eration was evaluated according to our previous publications.4,5 In brief,
allografts were photographed at 43 magnification and the area of the942 The Journal of Thoracic and Cardiovascular Surgobliterated lumen and the total area of lumen were measured using the
Image-Pro Plus software. The percent of the obliteration was calculated
by the area of fibrosis divided by the total area of lumen. Eight to 10 allo-
grafts were measured in each group. The data were used for statistical
analysis.ery c April 2013
FIGURE 2. Losing of epithelial cells in the transplanted trachea. Epithe-
lial cells are disappearing rapidly owing to ischemia–reperfusion injury in
the early stage (days 1-3 after tracheal transplantation) in all transplanted
trachea. The pseudoepithelial cells are regenerated from days 4 to 7 in
all allografts. The second loss of the regenerated epithelium occurred
from days 7 to 14 in all of the allografts except in Rag-1 KO mice, which
show a pattern similar to that of isograft controls.
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Data are presented as the mean standard error of the mean. The mac-
rophage, neutrophils, and CD3þT cell counts were compared using 1-way
analysis of variance followed by the Student t test for unpaired data with
Bonferroni correction. Square roots of tissue cell counts were compared us-
ing 1-way analysis of variance.
RESULTS
Loss of Epithelial Cells in Allografts
Using a widely established HTT model (Balb/C trachea
as donor and wild-type C57BL/6), we have observed the
histologic kinetics of allografts after transplantation from
the different groups and different time points. The results
confirmed our previous finding that the first complete loss
of the epithelium occurred in all transplanted tracheas on
day 3 after transplantation (Figures 1 and 2). The cause of
the first (phase I) epithelial loss is early ischemia–reperfu-
sion injury, and thus this also happened in Rag-1 KO
mice and the isograft control group (C57BL/6 into
C57BL/6; Figures 1 and 2). There was full reepithelializa-
tion of the basement membrane between 3 to 7 days in all
of the transplants. Interestingly, the second loss of epithelial
cells (phase II) was found in C57BL/6 WT mice from day 7
to day 12 (Figures 1 and 2). In contrast, there was no second
loss of epithelial cells in Rag-1 KO mice and isograft con-
trols (Figures 1 and 2). The results show that the second loss
of epithelial cells on day 12 is closely correlated with lumi-
nal obliteration on day 21 (Figures 1 and 2).
The Regenerated EpitheliumOriginates FromDonor
Basal Cells, Not From a Recipient Source
To determine the origin of the regenerated epithelial
cells, we used genetic GFP mice (on C57BL/6The Journal of Thoracic and Cabackground). First, we confirmed that the cells in trachea,
lung, small intestine, spleen, heart, and kidney (data not
shown) from GFP mice are GFP-positive cells. Then, using
Balb/C as donors and GFP mice as recipients, we found that
the regenerated epithelial cells in the allografts are GFP-
negative (Figure 3, A), evidence that these cells are of donor
origin. We did note a small portion of GFP-positive cells in
the epithelial layer, but these were verified to be CD3þ T
cells (Figure 4, A). Confirming this result, we found when
we used GFP mice as donors and Balb/C as recipients,
the regenerated epithelial cells were all GFP-positive,
evidence again that they are again of donor origin
(Figure 3, B). These results indicate that the regenerated ep-
ithelial cells originate from the donor, not from the recipi-
ents. Of note, in the isografts there were no inflammatory
or T cells seen infiltrating in the epithelial layer in the
isograft (Figure 4, B).
Leukocyte Infiltration
Macrophages infiltration was observed with a peak on
day 7 in the allografts of C57BL/6 wild-type mice, whereas
the macrophage infiltration reached a peak on day 12 in
Rag-1 KO mice (data not shown). However, the neutrophil
infiltration peak was on day 7 in all the allografts except on
day 3 in Rag-1 KO mice. Interestingly, the neutrophil infil-
tration vanished after day 7 in Rag-1 KO mice. These find-
ings indicate that the early infiltration (days 1-3) of the
macrophage and neutrophil were a reaction of acute injury
caused by ischemia–reperfusion. The CD3þ T cells may
play an important role in later neutrophil infiltration (days
4-21), because Rag-1 KO mice had no neutrophil infiltra-
tion during this time period. The macrophage infiltration
was delayed in Rag-1 KO mice.
To determinewhether there is an adaptive immune role of
CD3þT cell in development of BO, we assessed infiltration
of CD3þT cells via immunohistochemistry in the different
groups. The results showed that few CD3þ T cells were
detected in allografts during the first 3 days after transplan-
tation. Increasing infiltration of CD3þT cells was apparent
on day 7 (Figure 4, A), peaked on days 7 to 12 in different
allografts, and significantly decreased afterward (data not
shown). However, the number of infiltrating CD3þT cells
was significantly abrogated in the epithelial layer of iso-
grafts (C57BL/6 to C57BL/6, Figure 4, B). As expected,
only few na€ıve CD3þ T cells were detected in Rag-1 KO
mice (data not shown). These results suggest that CD3þ
T cells infiltrating into the epithelial layer may be a key con-
tributor for second loss of epithelial cells in the transplanted
trachea.
Epithelial/basal Cells Harvest for Allograft Injection
The epithelial cells from recipient mice were isolated
using digestion solution with 0.01% collagenase A as de-
scribed in the Methods section. After digestion, the tracheasrdiovascular Surgery c Volume 145, Number 4 943
FIGURE 3. Immunohistochemical staining of GFP in allografts on day 7 after tracheal transplantation. A, Representative picture of GFP staining in al-
lograft (Balb/c to GFP/C57BL/6) on day 7. B, Representative picture of GFP staining in allograft (GFP/C57BL/6 to Balb/c) on day 7. Cells stained brown/
dark brown indicate GFP-positive cells. All sections were counterstained lightly with hematoxylin for viewing negatively stained cells. Normal IgG was
used as controls. Black arrows indicate epithelial cells. The grey arrows indicate basal cells. The magnifications are indicated in the pictures. GFP, Green
fluorescent protein; IgG, immunoglobulin G.
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Figure E1, the epithelial cells were not detached within
15 minutes but were detached after 30 minutes. Most of
the epithelial cells, including the basal cells, were detached
by 1 hour of digestion.944 The Journal of Thoracic and Cardiovascular SurgInjection of the Isolated Epithelial Cells From
Recipients Prevents the Second Loss of Epithelial
Cells and BO Development
After injectionof the isolatedepithelial cells fromrecipients
into the allografts on day 3 after transplantation, theery c April 2013
FIGURE 4. Immunohistochemical staining of CD3þT-cells in (A) the allografts of Balb/c to GFP/C57BL/6 and in (B) isograft of C57BL/6 to C57BL/6.
Cells stained brown indicate CD3þT-cell infiltration. All sections were counterstained lightly with hematoxylin for viewing negatively stained cells. The
slides were stained with anti-CD3 antibody. Normal IgG was used as control. The magnifications are indicated in the pictures. GFP, Green fluorescent
protein; IgG, immunoglobulin G; BC, Balb/c.
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ithelial cells did not undergo disappearance when compared
with the control groups on day 12 (Figure 5, A). Luminal
fibro-obliteration was observed from days 12 to 21 in all the
experimental groups except isograft control and Rag-1 KO
groups. The luminal obliteration of the allografts that received
epithelial injection was significantly less on day 21 (P¼ .007)
comparedwith the 1XPBScontrol group (Figure 5,B). It is no-
table that the luminal obliterationwasmarkedly decreased not
only in isografts and Rag-1 KOmice, but also in the recipient
epithelial cell–injected allografts.
DISCUSSION
A mouse HTT model used in these studies is often re-
ferred to as obliterative airway disease3,6 because it
displays several features that are similar to human BO.
Heterotopic tracheas transplanted intoHLA-mismatched re-
cipients develop injury that can be divided into an acute
phase (days 1-3) characterized by loss of epithelial cells
and inflammation resulting from ischemia–reperfusion
injury and a later phase (days 4-12) involving the adaptive
immune system with lymphocyte infiltration and eventually
fibro-obliteration (days 13-28). We acknowledge that the
mouse HTT model has significant shortcomings: MostThe Journal of Thoracic and Canotably, this model is neither vascularized nor aerated and
is a large airway model for a small airway disease. There
are other models used to study BO, including an orthotopic
tracheal model.17 However, the orthotopic model is
similarly a large airwaymodel, nonvascularized, technically
more challenging, and unable to uniformly develop histo-
pathologic BO. A single lung transplantation has been suc-
cessfully performed in mice18,19; however, these
transplanted lung allografts have not been shown to
reliably develop histopathologic lesions of BO. On the
other had, human small airways have an epithelial layer,
whereas the mouse small airways lack an epithelial layer;
therefore, mouse large airway with the epithelial cells may
better represent human small airway in this animal model.
Previous publications have shown the regenerated epithe-
lial cells to be of donor origin in the early stage, but these
studies were in rat and dog tracheal transplantation
models.7-9 Our current study confirmed these results using
a mouse HTT model. In this model, there is early loss of
epithelial cells (phase I) caused by ischemia–reperfusion
injury, followed by regeneration and then a second loss of
epithelial cells (phase II), which occurs only in allografts
and is believed to be immunologic in origin. Our current
result revealed that Rag-1 KO mice, which lack T and Brdiovascular Surgery c Volume 145, Number 4 945
FIGURE 5. A, Injection of recipient epithelial cells prevents the second epithelial loss on day 12 (top panel) when compared with noninjectedmice (bottom
panel). B, Comparison of luminal obliteration of the allografts with and without epithelial injection on day 21. Data shown are the mean  standard de-
viation. *P ¼ .007, n ¼ 6. BC, Balb/c; EPC, epithelial cells.
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the secondary immunologic loss. Additionally, we usedGFP
recipients and donors to show the origin of the regenerated
epithelial cells to be of donor origin. We also used this strain
to detect the integration of injected recipient epithelial cells
into the donor trachea. The novel finding of this study is that
injection of epithelial cells, which were isolated from recip-
ient trachea, could block BO development by preventing the
second loss of epithelial cells in the tested allografts.
Regeneration and restoration of the airway epithelium af-
ter physical, viral, or bacterial injury plays a role in numerous946 The Journal of Thoracic and Cardiovascular Surgrespiratory diseases, such as chronic bronchitis, asthma, and
cystic fibrosis.20 Data from published animal models show
epithelial regeneration to be a complex process involvingmi-
gration of the basal cells adjacent to the injury, rapid restora-
tion of tight junctions followed by squamous metaplasia,
active mitosis leading to basal and mucous cell hyperplasia,
and progressive redifferentiation with the emergence of cili-
ated and mucous cells, and ciliogenesis. This process allows
for the regeneration of a functionalmucociliary epithelium.20
Evidence suggests that stem/progenitor cells play an im-
portant role in epithelial regeneration after trachea/lungery c April 2013
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recipient epithelium into a heterotopic donor trachea
before orthotopic transplantation was previously published
as a successful case report by the Leuven group.25 Because
the second loss of epithelial cells is associated with alloim-
mune reaction, we explored the possibility that injection of
epithelial stem/progenitor cells from recipients may prevent
BO development in the mouse HTT model.
Several potential sources of stem/progenitor cells for air-
way epithelium have been identified, including endogenous
stem/progenitor cells present in the respiratory tract and/or
from other tissues in the body; these latter cells can be trans-
ported to the lung, where they can divide and grow.13 In this
study, we focus on the potential function of local epithelial
stem/progenitor cells (basal and Clara cells) after tracheal
transplantation. Inasmuch as both basal and secretory epithe-
lial cells may serve as stem/progenitors during trachea/lung
injuries, we investigated the use of mixed epithelial cells
from recipients in our current study. The results demonstrated
that injection of tracheal epithelial cells was able to prevent
the second loss of epithelial cells and, as a consequence, pre-
vented BO development. Our results provide preclinical ev-
idence that epithelial stem/progenitor cells may be a viable
treatment strategy for BO after lung transplantation.
In conclusion, our results show that injection of epithelial
stem/progenitor cells obtained from recipients into the allo-
grafts on day 3 prevents second loss of epithelial cell in the
allografts, which subsequently decreased BO development
in a mouse HTT model. These results suggest that using ep-
ithelial stem/progenitor cells may provide a novel therapeu-
tic strategy to prevent BO after lung transplantation.
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FIGURE E1. Histologic examination of epithelial cells after digestion with 0.01% collagenase A in the trachea of GFP/C57BL/6 mice. The epithelial
layers are intact in the nondigested normal trachea and 15-minutes digestion trachea. Epithelial cells detached after digestion of 30 minutes and completely
detached after 1 hour of digestion. Black arrows indicate epithelial cells. The gray arrows indicate basal cells. The magnifications are indicated on the pic-
tures. GFP, Green fluorescent protein.
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